GLP-1RAs have gained significant popularity over the past decade due to their effectiveness in improving glycemic control, aiding weight loss, and providing cardiovascular and renal benefits. Despite their growing use, limited evidence exists regarding their potential respiratory adverse effects. Previous observations have noted associations between GLP-1RAs and gastroesophageal reflux disease (GERD), as well as vagal nerve stimulation—both of which could theoretically contribute to chronic cough. However, until now, this relationship had not been systematically evaluated.
The study, led by Tyler J. Gallagher from the Caruso Department of Otolaryngology–Head & Neck Surgery at the Keck School of Medicine, utilized a massive pool of electronic health records from 70 US health systems. The dataset included clinical information from April 2005 to April 2025, allowing the team to assemble one of the largest cohorts to date examining respiratory risks among GLP-1RA users.
A total of 427,555 adults with type 2 diabetes who were prescribed a GLP-1RA were compared with 1,614,495 patients who received different second-line medications such as DPP-4 inhibitors, SGLT2 inhibitors, and sulfonylureas. After applying propensity score matching to balance demographic and clinical factors, the researchers conducted Cox regression analyses to measure the risk of developing chronic cough.
To determine whether reflux-related cough contributed to these findings, the researchers conducted an additional analysis excluding individuals with known GERD.
Key findings:
- GLP-1RA users showed a modest but statistically significant increase in chronic cough compared with most other diabetes medication groups.
- The adjusted hazard ratio (aHR) for chronic cough was 1.12 when compared with all non–GLP-1RA medications.
- The risk increased further when compared specifically with DPP-4 inhibitors (aHR, 1.18) and sulfonylureas (aHR, 1.32).
- No significant difference in chronic cough risk was observed when comparing GLP-1RAs with SGLT2 inhibitors (aHR, 1.03).
- After excluding individuals with GERD, the association between GLP-1RA use and chronic cough remained and, in some cases, strengthened.
- In the GERD-free subgroup, GLP-1RA users had a 29% higher risk of chronic cough than users of non–GLP-1RA medications (aHR, 1.29).
- The elevated risk continued to be observed when compared separately with DPP-4 inhibitors, SGLT2 inhibitors, and sulfonylureas.
While the study does not establish causation, the authors note that these observations raise important questions for clinicians and patients using or considering GLP-1RAs. They emphasize the need for dedicated mechanistic studies to explore whether drug-induced changes in gastric motility, neural pathways, or airway sensitivity may be contributing factors.
"As GLP-1RAs continue to be prescribed at unprecedented rates, understanding their full safety profile—including potential respiratory effects—remains a critical area for future research," the authors concluded.
Reference:
Gallagher TJ, Razura DE, Li A, Kim I, Vukkadala N, Barbu AM. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough. JAMA Otolaryngol Head Neck Surg. Published online November 26, 2025. doi:10.1001/jamaoto.2025.4181
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.